Krystal Biotech (KRYS) Competitors $148.17 -1.57 (-1.05%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$150.57 +2.40 (+1.62%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KRYS vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, QGEN, ASND, BBIO, and BPMCShould you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Krystal Biotech vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris QIAGEN Ascendis Pharma A/S BridgeBio Pharma Blueprint Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Do insiders and institutionals have more ownership in ITCI or KRYS? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 13.7% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate ITCI or KRYS? Intra-Cellular Therapies presently has a consensus target price of $109.70, indicating a potential downside of 16.81%. Krystal Biotech has a consensus target price of $213.75, indicating a potential upside of 44.26%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ITCI or KRYS more profitable? Krystal Biotech has a net margin of 37.17% compared to Intra-Cellular Therapies' net margin of -14.07%. Krystal Biotech's return on equity of 14.64% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Krystal Biotech 37.17%14.64%13.28% Which has higher earnings and valuation, ITCI or KRYS? Krystal Biotech has lower revenue, but higher earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Krystal Biotech$333.45M12.84$89.16M$4.1635.62 Which has more volatility & risk, ITCI or KRYS? Intra-Cellular Therapies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Does the media favor ITCI or KRYS? In the previous week, Krystal Biotech had 17 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 18 mentions for Krystal Biotech and 1 mentions for Intra-Cellular Therapies. Krystal Biotech's average media sentiment score of 0.39 beat Intra-Cellular Therapies' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKrystal Biotech beats Intra-Cellular Therapies on 13 of the 17 factors compared between the two stocks. Get Krystal Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRYS vs. The Competition Export to ExcelMetricKrystal BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.28B$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio35.6220.8528.2620.26Price / Sales12.84300.55435.95101.33Price / Cash31.9542.1137.1257.67Price / Book4.507.638.045.49Net Income$89.16M-$55.05M$3.19B$250.45M7 Day Performance3.61%8.43%3.62%4.78%1 Month Performance8.10%8.14%5.98%9.58%1 Year Performance-27.06%1.62%29.39%16.41% Krystal Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRYSKrystal Biotech4.6739 of 5 stars$148.17-1.0%$213.75+44.3%-27.1%$4.28B$333.45M35.62210Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionITCIIntra-Cellular Therapies0.6591 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.0955 of 5 stars$20.52+1.1%$37.60+83.2%-20.9%$13.02B$3.12B11.662,682Positive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.763 of 5 stars$15.08flat$16.95+12.4%-8.8%$12.59B$325.54B22.8527,811MRNAModerna4.305 of 5 stars$29.90-1.9%$46.61+55.9%-72.3%$11.79B$3.24B-3.425,800Trending NewsRGCRegencell Bioscience0.3653 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Gap UpHigh Trading VolumeVTRSViatris2.9044 of 5 stars$9.20-1.3%$10.40+13.0%-18.9%$10.94B$14.74B-2.9032,000QGENQIAGEN3.5769 of 5 stars$47.49-1.8%$49.40+4.0%+17.4%$10.75B$1.98B119.075,765ASNDAscendis Pharma A/S3.6014 of 5 stars$175.98+1.0%$220.67+25.4%+26.7%$10.65B$393.54M-28.021,017News CoverageAnalyst ForecastBBIOBridgeBio Pharma4.6657 of 5 stars$43.50-1.1%$58.85+35.3%+71.3%$8.35B$221.90M-12.32400Analyst UpgradeBPMCBlueprint Medicines1.2225 of 5 stars$128.40+0.0%$128.06-0.3%+9.8%$8.29B$508.82M-51.98640Insider Trade Related Companies and Tools Related Companies ITCI Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives RGC Alternatives VTRS Alternatives QGEN Alternatives ASND Alternatives BBIO Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRYS) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
